![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » I-Flow Announces Two-Year Study Results for ON-Q
I-Flow Announces Two-Year Study Results for ON-Q
March 16, 2005
I-Flow has announced that a long-term study on the use of ON-Q PainBuster following breast cancer surgery showed that the benefits of ON-Q not only reduced acute pain after surgery, but also helped patients have less pain with daily activities over time.
The study initially showed that the use of ON-Q PainBuster following surgery for removal of axillary lymph nodes in 27 patients with breast cancer resulted in decreased pain and narcotics use immediately following the operation. Also, patients who received postsurgical pain relief with ON-Q PainBuster continued to have significantly better scores when tested for shoulder function and pain with daily activities.
"Removal of the lymph nodes from under a woman's arm is an invasive procedure that can affect her mobility throughout the course of her life," said lead study investigator Scott Schell. "In my experience following up with patients over time, it was very evident that patients treated with ON-Q simply felt better and had improved flexibility versus patients who did not receive ON-Q for their postsurgical pain."
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct